The mode of action and clinical pharmacology of gliclazide: a review.

@article{Campbell1991TheMO,
  title={The mode of action and clinical pharmacology of gliclazide: a review.},
  author={D. B. Campbell and Rodolphe Lavielle and Christopher Nathan},
  journal={Diabetes research and clinical practice},
  year={1991},
  volume={14 Suppl 2},
  pages={
          S21-36
        }
}
Gliclazide is a sulphonylurea drug with an intermediate half-life of around 11 hours. It is extensively metabolised, and renal clearance accounts for only 4% of total drug clearance. The molecule contains an azabicyclo-octyl group which confers special properties on the basic sulphonylurea moiety. Gliclazide stimulates insulin secretion through the beta cell sulphonylurea receptor, and possibly through a direct effect on intracellular calcium transport. It specifically improves the abnormal… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED 90% COVERAGE

Gliclazide Modified Release

VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid?

Emanuele Cozzani, Giovanni Di Zenzo, +4 authors Aurora Parodi
  • European Journal of Dermatology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2000
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations